

**OMTM, Volume 17**


## **Supplemental Information**

### **Increasing CRISPR Efficiency and Measuring Its Specificity in HSPCs Using a Clinically Relevant System**



**Jenny Shapiro, Ortal Iancu, Ashley M. Jacobi, Matthew S. McNeill, Rolf Turk, Garrett R. Rettig, Ido Amit, Adi Tovin-Recht, Zohar Yakhini, Mark A. Behlke, and Ayal Hendel**

## Supplemental Information


### Supplemental Figures and Legends




**Figure S1. Screening for most active *RAG2* and *RAG1* gRNAs.** Five potential gRNAs were identified by DESKGEN™ CRISPR software for *RAG2* (left) and *RAG1* (right) genes. The DNA sequence of each guide was cloned into the px330 plasmid and genome editing experiments were performed in the K562 cell line. The most active gRNAs (*RAG2* gRNA 2 and *RAG1* gRNA 3) were chosen for downstream experiments. Bars represent mean indel editing percentages analyzed by TIDE  $\pm$  SEM (n=3). Editing percentages are designated above the bars.

**A****B**


**Figure S2. On-target editing detection in CD34+ HSPCs by NGS compared to TIDE and ICE chromatogram decomposition algorithms.** (A) Amplicons of *RAG2* and *RAG1* on-target sites from CD34+ HSPCs (Figure 1) were Sanger sequenced, and chromatograms were analyzed by decomposition with TIDE software. Indel-editing frequencies quantified by NGS (Figure 1) were plotted against the TIDE quantification values. (B) Chromatograms were analyzed by decomposition with ICE software, and indel-editing frequencies were plotted against the TIDE analysis.



**Figure S3: *RAG2* and *RAG1* gRNAs off-target sites were found dispersed throughout the genome.** Off-target sites identified by GUIDE-seq in HEK293-Cas9 cells using Alt-R 2-part XT gRNA were categorized according to their genomic location either in exons, introns, intron-exon junction, non-coding RNA, or non-transcribed DNA.



**Figure S4: Correlation between the GUIDE-seq read counts and the number of mismatches.** GUIDE-seq read counts identified in HEK293-Cas9 cells, following editing with *RAG2* (A) and *RAG1* (B) Alt-R 2-part XT gRNAs were plotted against the number of mismatches in each site (Spearman correlation).



**Figure S5: Correlation between rhAmpSeq and GUIDE-seq.** Genomic DNA (gDNA) samples of the HEK293-Cas9 and HEK293 cells used in the GUIDE-seq experiments were subjected to rhAmpSeq analysis. The rhAmpSeq indel-editing percentages of *RAG2* (**A**) and *RAG1* (**B**) sites are plotted against the GUIDE-seq measurements, presented as a percentage normalized to 100% of the on-target site (Spearman correlation).  $P < 0.01$ .

## Supplemental Tables

Gene	gRNA name	gRNA sequence	Genomic position
<b>RAG2</b>	gRNA 1	AGAAACTATGTCTCTGCAGA	Chr11:36594156-36594175
	gRNA 2*	TGAGAAGCCTGGCTGAATTA	Chr11:36594109-36594128
	gRNA 3	AACATAGCCTTAATTCAGCC	Chr11:36594119-36594138
	gRNA 4	AAATTCATCAGTGAGAAGCC	Chr11:36594098-36594117
	gRNA 5	TTCTCACTGATGAATTTTGA	Chr11:36594077-36594096
<b>RAG1</b>	gRNA 1	TGGGAAAGAGGCTGCCATGC	Chr11:36573303-36573322
	gRNA 2	TCCAAGGTGGGTGGGAAAG	Chr11:36568025-36579756
	gRNA 3*	AACTGAGTCCCAAGGTGGGT	Chr11:36573322-36573341
	gRNA 4	GAACTGAGTCCCAAGGTGGG	Chr11:36573323-36573342
	gRNA 5	AGCCTCTTCCACCCACCT	Chr11:36573310-36573329

**Table S1:** Five potential gRNA sequences for *RAG2* and *RAG1* genes, were identified by DESKGEN™ CRISPR software. Asterisks indicate the gRNAs used in all subsequent experiments.

**Table S2 (Submitted separately as an Excel file): GUIDE-seq in HEK293-Cas9 cells edited with Alt-R 2-part XT gRNA.** Full list of *RAG2* and *RAG1* off-target sites, as identified by GUIDE-Seq and their genomic details.

## Supplemental Methods and Materials

**gRNA Competition:** Five 20 bp gRNAs, closest to the initiation start codon, were chosen for each target gene by DESKGEN™ CRISPR bioinformatics tool (see **Table S1** for sequences).<sup>1</sup> The chosen oligonucleotides were cloned, as previously described,<sup>2</sup> into px330 sgRNA expression plasmid vectors (Addgene plasmid #42230) containing a human codon-optimized SpCas9 expression cassette and a human U6 promoter driving the expression of the sgRNA. Human K562 cells were cultured in RPMI 1640, supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 1% L-glutamine (Biological Industries Ltd).  $1 \times 10^6$  cells were electroporated with 5  $\mu$ g of each of the cloned expression plasmids. Electroporation was performed in 100  $\mu$ l nucleofection buffer (containing 100 mM KH<sub>2</sub>PO<sub>4</sub>, 15 mM NaHCO<sub>3</sub>, 12 mM MgCl<sub>2</sub>  $\times$  6H<sub>2</sub>O, 8 mM ATP, 2 mM glucose (pH 7.4)) using the Lonza 2b Nucleofector (program T-016). 72 h post-electroporation gDNA was extracted by QuickExtract (Lucigen Corporation, WI), and indel editing frequencies were determined by chromatogram decomposition (TIDE software<sup>3</sup>).

**On-target indel-editing frequency quantification using decomposition analysis:** The following specific primers were used to amplify the gDNA sequences flanking the on-target sites of the genes of interest: RAG2\_Fw: 5'-ACGGATTCTTGGGAAATGTG-3', RAG2\_Re: 5'-GATGGTGTCATTTTTGGCAAT-3', and RAG1\_Fw: 5'- CCTTAAGGTTTTTGTGGAAGGA-3', RAG1\_Re: 5'- GGGCTTTTAACAATGGCTGA-3'. Amplicons were Sanger sequenced, and indel-editing frequencies were quantified by chromatogram decomposition using the TIDE software compared to mock-electroporated controls.



## Supplemental References

1. Hough, SH, Ajetunmobi, A, Brody, L, Humphryes-Kirilov, N, and Perello, E (2016). Desktop Genetics. *Per Med* **13**: 517-521.
2. Ran, FA, Hsu, PD, Wright, J, Agarwala, V, Scott, DA, and Zhang, F (2013). Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* **8**: 2281-2308.
3. Brinkman, EK, Chen, T, Amendola, M, and van Steensel, B (2014). Easy quantitative assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res* **42**: e168.